Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sublivac Grasses is a sublingual allergen extract immunotherapy indicated for the treatment of IgE-mediated allergic rhinitis, allergic conjunctivitis, and mild allergic asthma triggered by grass pollen. It is designed to induce immune tolerance to specific grass pollens through repeated sublingual administration. The formulation contains allergen extracts from Lolium perenne (perennial ryegrass), Phleum pratense (timothy grass), and Poa pratensis (Kentucky bluegrass). The mechanism of action involves immunomodulation—specifically, the induction of immune tolerance by shifting the immune response away from an IgE-mediated pathway. This therapy is suitable for both adults and children aged five years and older with confirmed diagnosis via skin prick test or serum-specific IgE testing[1][6]. Clinical studies have demonstrated that sublingual immunotherapy with grass pollen extracts can reduce symptoms and medication use in patients with seasonal allergies[1][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sublivac Grasses.